Ipsen’s Onivyde regimen granted FDA approval to treat pancreatic cancer
15 Feb 2024
Clinical ResultDrug ApprovalPhase 3ASCO
Preview
Source: PMLiVE
Ipsen’s Onivyde (irinotecan liposome injection) regimen has been approved by the US Food and Drug Administration (FDA) to treat pancreatic cancer.
Onivyde plus oxaliplatin, fluorouracil and leucovorin (Nalirifox) can now be used as a first-line treatment for adults with metastatic pancreatic adenocarcinoma (mPDAC).
PDAC is the most common type of pancreatic cancer, with approximately 60,000 people diagnosed with the disease in the US every year.
Since there are no specific symptoms in the early stages, PDAC is often detected late, after the disease has spread to other parts of the body.
The FDA’s decision on the Onivyde regimen was supported by positive results from the late-stage NAPOLI 3 trial, in which Nalirifox was associated with a statistically significant improvement in median overall survival of 11.1 months compared to 9.2 months for patients treated with the standard regimen of Bristol Myers Squibb’s Abraxane (nab-paclitaxel) plus gemcitabine.
Nalirifox also demonstrated a statistically significant improvement in median progression-free survival of 7.4 months versus 5.6 months for the standard care group.
“The results from the phase 3 NAPOLI 3 trial represent the first positive data for an investigational regimen in first-line metastatic pancreatic adenocarcinoma versus the currently approved nab-paclitaxel and gemcitabine regimen,” explained Christelle Huguet, executive vice president and head of research and development at Ipsen.
“With [the] approval, this Onivyde (Nalirifox) regimen can now offer a potential new standard of care treatment option with proven survival benefits for people living with mPDAC in the US,” she added.
Onivyde is already approved in major markets, including the US, in combination with fluorouracil and leucovorin to treat adults with mPDAC who are experiencing disease progression following gemcitabine-based therapy.
Commenting on the latest Onivyde regimen approval, Dr Zev Wainberg, professor of medicine and co-director of the UCLA GI oncology programme, said: “Given the reality of this aggressive form of cancer and the complexity of the disease, every advance in the treatment landscape represents a meaningful improvement in patient outcomes.”
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Targets
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.